Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are ...

NORTHAMPTON, MA / ACCESS Newswire / March 18, 2025 / We're proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...